Glykogenfosforyláza BB jako marker srdečního poškození při vysokodávkové chemoterapii během transplantace krvetvorných buněk

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F07%3A00003661" target="_blank" >RIV/00216208:11150/07:00003661 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60162694:G44__/07:00001801 RIV/00216208:11150/07:00003642 RIV/00179906:_____/07:00000283

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Glycogen phosphorylase BB as a marker of cardiac toxicity during high-dose chemotherapy followed by hematopoietic cell transplantation

Popis výsledku v původním jazyce

The aim of the study was to assess cardiac toxicity during myeloablative preparative regimen (PR) and hematopoietic cell transplantation (HCT) with biomarkers of cardiac injury: glycogen phosphorylase BB (GPBB), heart fatty acid binding protein (H-FABP),cardiac troponins (cTnT, cTnI), creatine kinase MB (CK-MB mass), myoglobin. Nineteen patients (mean age 42.8+-10.0 years, 13 males) with acute leukemia were studied. GPBB became elevated (above 7.30 ?g/L) in 5 (26.3%) patients after PR, remained elevated in 5 (26.3%) after HCT and in 1 (5.3%) 14 days after HCT. Other markers remained within the reference range in all patients. Our findings suggest that GPBB released from cardiomyocytes after myeloablative PR followed by HCT could be a new marker of acute subclinical cardiotoxicity. The predictive value for development of cardiomyopathy is unclear and further studies will be needed in this context.

Název v anglickém jazyce

Glycogen phosphorylase BB as a marker of cardiac toxicity during high-dose chemotherapy followed by hematopoietic cell transplantation

Popis výsledku anglicky

The aim of the study was to assess cardiac toxicity during myeloablative preparative regimen (PR) and hematopoietic cell transplantation (HCT) with biomarkers of cardiac injury: glycogen phosphorylase BB (GPBB), heart fatty acid binding protein (H-FABP),cardiac troponins (cTnT, cTnI), creatine kinase MB (CK-MB mass), myoglobin. Nineteen patients (mean age 42.8+-10.0 years, 13 males) with acute leukemia were studied. GPBB became elevated (above 7.30 ?g/L) in 5 (26.3%) patients after PR, remained elevated in 5 (26.3%) after HCT and in 1 (5.3%) 14 days after HCT. Other markers remained within the reference range in all patients. Our findings suggest that GPBB released from cardiomyocytes after myeloablative PR followed by HCT could be a new marker of acute subclinical cardiotoxicity. The predictive value for development of cardiomyopathy is unclear and further studies will be needed in this context.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2007

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Annals of Oncology

ISSN

0923-7534

e-ISSN

—

Svazek periodika

18

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

1

Strana od-do

2041-2041

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—